Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-98 in Primary Treatment of HIV-infected Patients
NCT06560489Phase 2Completed
- Sponsor
- Shanxi Kangbao Biological Products
- Start
- Sep 2024
- Primary completion
- Jan 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of lipovirtide in human immunodeficiency virus infection (HIV), sponsored by Shanxi Kangbao Biological Products. Started Sep 2024; status: completed.
02
Drugs
lipovirtide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06560489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06560489.